NeuroPace's third quarter broke the growth story that management had spent the year building. The company reported a loss of $0.10 per share on revenue of $23.1 million. Consensus was a loss of $0.06 per share and the Earnings Whisper number was a loss of only $0.01, so the 900.0% negative surprise reflects a small absolute gap on a near-breakeven base. The revenue miss was more consequential: sales came in 14.6% below the $27.05 million consensus.

The year-over-year comparisons need context. Earnings Whispers shows revenue falling 15.5% from a year ago. The company's continuing-operations presentation shows only a 1.1% decline, because it reclassifies the exited DIXI Medical business as discontinued operations, and core RNS revenue grew 1.4%. Either way, the conclusion is the same. RNS growth fell from 26% in the fourth quarter of 2025, 19.5% in the first quarter and 21.3% in the second quarter to roughly 1%, after management had guided to about 20% for the third quarter on its last call. Per-share earnings grew 9.1% from a year ago, but that improvement says little about the franchise's trajectory.

The quality of the quarter splits sharply between the top line and everything beneath it:

• Non-GAAP gross margin rose to 84.8%, up from 82.8% a year ago and a steady step-up from earlier in the year.
• Adjusted EBITDA turned positive at $0.4 million, versus a $1.3 million loss in the year-ago quarter.
• GAAP net loss from continuing operations narrowed to $3.3 million from $4.9 million.

That profitability deserves scrutiny. Non-GAAP operating expenses fell to $19.2 million partly because sales commissions and other variable compensation dropped. In other words, part of the margin leverage came from the revenue shortfall itself.

The call made clear that the miss was largely self-inflicted and concentrated. CEO Joel Becker attributed the shortfall to several of the largest accounts, which faced staffing, physician-availability and diagnostic-capacity problems. He also pointed to a mid-year restructuring of sales leadership and field clinical engineers that "created more disruption than anticipated." The call analysis adds two further factors:

• Exiting the SEEG distribution business cost NeuroPace operating-room and neurosurgeon touchpoints that had fed the large-account pipeline.
• Analysts raised the risk of case leakage to VNS, which benefits from a large reimbursement increase.

Active prescribers again hit a record, and management said fourth-quarter scheduled cases have begun to recover. Still, the tone shifted from the confidence of a "transformational year" to something closer to apology and accountability.

Guidance is where the damage compounds. Full-year revenue guidance fell to $91 million to $92 million from $99.5 million to $101.5 million. Implied RNS growth dropped to 10% to 11% from 21% to 23%, and the implied fourth-quarter RNS growth rate is only about 5%. Management raised gross margin guidance to 83.0% to 83.5% and cut operating expense guidance by roughly $5 million to $6 million. Even so, the adjusted EBITDA loss forecast widened to $8.5 million to $9.5 million.

Preliminary 2027 commentary was also notable. Management framed RNS growth at about 15%, with 10% to 15% in the first half, and that outlook excludes any IGE contribution. That falls short of the 20%-plus long-term framework repeated on every prior call, and bears now have legitimate credibility ammunition.

The pipeline is the counterweight, and it did advance:

• **Remote Care:** a PMA supplement has been submitted, with possible approval in the second quarter of 2027.
• **AURORA:** enrollment has begun in this real-world evidence study targeting adolescents, which management sizes at about 70,000 patients.
• **Reimbursement:** CMS's final 2027 outpatient rule raises RNS replacement payment by about 11%.
• **IGE:** the amendment is due around year end, but approval is now assumed for mid-2027, a year later than originally planned.

The balance sheet leaves limited room for further slippage. Cash and investments stand at $49.5 million, down from $51.9 million in the prior quarter, against $59.2 million in long-term debt.

The market had partly anticipated trouble. Shares were at $12.52 before the report, down 11.6% since the open following the August release and 15.6% below the 200-day moving average. They sat just 4.3% above a 52-week low of $12.00 set November 3, and roughly 20% beneath the September high of $15.56. Investor sentiment moved from essentially neutral to modestly negative, a meaningful but not dramatic deterioration. Price and AVWAP trend readings are negative. The positive sequential-growth reading looks backward-facing against a fourth-quarter guide implying about 5% growth.

The bottom line is that NeuroPace converted a growth story into a show-me story in a single quarter. Margins, cost discipline and regulatory milestones give the long-term case real substance. However, a 1% RNS print, a roughly $9 million guidance cut and a sub-framework 2027 outlook mean investors will need evidence of recovering case volumes at large accounts before the pipeline narrative can carry the stock again.